Treatment of Myelodysplastic Syndromes Comparing Hydralazine/Ac. Valproic and Supportive Care in Patients Not Candidates, Refractory and/or Intolerant to Intensive Chemotherapy

NCT01356875 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

42

Enrollment

OTHER_GOV

Sponsor class

Conditions

Myelodysplastic Syndrome

Interventions

DRUG: BSC
DRUG: HIDRA/VPA

Sponsor

Basque Health Service